GlassScriptPhysician profile
Evan C Adelstein
NPI 1376623090
$8,100.79
in general payments reported to CMS, 2019-2025
26 companies · $1,720 in 2025
The $1,720 reported for 2025 was less than what a typical Clinical Cardiac Electrophysiology provider received nationally (typical 2025 total: $2,477).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $679 · 2021: $144 · 2022: $708 · 2023: $1,136 · 2024: $3,715 · 2025: $1,720.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $4,336 · Food and Beverage: $2,235.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $4,335.73 |
| Food and Beverage | $2,234.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $3,835.32 | 2022-2025 | Aveir, Quadra Assura, Navitor |
| Medtronic, INC. | $1,650.19 | 2021-2025 | Evera Mri Xt Dr Surescan, Selectsecure, Azure Xt Dr Mri Surescan |
| Medtronic Vascular, INC. | $585.63 | 2019 | |
| Biosense Webster, INC. | $426.47 | 2021-2025 | Carto 3 |
| Cvrx, INC. | $289.29 | 2023-2025 | Barostim Neo System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $228.67 | 2023-2025 | Jardiance |
| Boston Scientific Corporation | $192.89 | 2019-2025 | General - Therapies |
| Atricure, INC. | $179.83 | 2022 | |
| Scpharmaceuticals INC. | $86.59 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $77.63 | 2024-2025 | |
| Pfizer INC. | $64.47 | 2022-2023 | |
| Janssen Pharmaceuticals, INC | $48.79 | 2023-2024 | Xarelto |
| Baxter Healthcare | $47.45 | 2025 | Hillrom - Carnation Ambulatory Monitor |
| Actelion Pharmaceuticals US, INC. | $47.21 | 2024-2025 | Uptravi, Opsumit |
| Alnylam Pharmaceuticals INC. | $45.51 | 2025 | Onpattro |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $40.23 | 2022-2025 | |
| Medicomp INC | $36.79 | 2025 | Telepatch Cardiac Monitor |
| Bridgebio Pharma, INC. | $34.23 | 2025 | Attruby |
| Regeneron Healthcare Solutions, INC. | $32.85 | 2025 | Evkeeza |
| Lexicon Pharmaceuticals, INC. | $31.34 | 2024 | |
| Merck Sharp & Dohme LLC | $30.27 | 2024-2025 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $29.01 | 2024-2025 | Eliquis, Camzyos |
| Astrazeneca Pharmaceuticals LP | $23.98 | 2025 | Wainua |
| Mannkind Corporation | $19.11 | 2025 | |
| Novo Nordisk INC | $17.04 | 2025 | Wegovy |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Evan Adelstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.